Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Cmv Hyperimmune Globulin

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT01376778Phase 3Completed

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT03973359Not ApplicableUnknown

Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy

Showing all 2 trials

Research Network

Common Treatments

  • Cmv Hyperimmune Globulin1
  • Hygienic Recommendations1

Active Sponsors

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1
  • Fondazione IRCCS Policlinico San Matteo di Pavia1
  • The George Washington University Biostatistics Center1
  • Fondazione Regionale per la Ricerca Biomedica1

Top Investigators

Related Conditions

  • Congenital Cytomegalovirus Infection2

Activity Timeline